ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript
ANI Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.937 EPS, expectations were $0.98.
Ani Pharmaceuticals Inc (ANIP)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 958,533 | $66,263,386 | -15% | 1.95% |
| 2. | Deep Track Capital David Kroin | 822,001 | $56,824,929 | +38% | 1.62% |
| 3. | Tang Capital Management Kevin C. Tang | 150,000 | $10,369,500 | 1.07% | |
| 4. | Citadel Investment Group Ken Griffin | 118,766 | $8,210,294 | -32% | 0% |
| 5. | Sio Capital Michael Castor | 87,354 | $6,038,782 | 1.79% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.69 | 7,224 | 169,650 | 2022-03-21 | Filing | ||
| $27.76 | 5,000 | 53,388 | 2022-03-21 | Filing | ||
| $27.87 | 5,000 | 393,226 | 2022-03-21 | Filing | ||
| $27.15 | 5,000 | 388,226 | 2022-03-18 | Filing | ||
| $27.65 | 5,000 | 5,000 | 2022-03-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $62.00 | 2,743 | Officer, Director | 632,620 | 2024-07-18 | Filing | |
| $63.16 | 14,257 | Officer, Director | 635,363 | 2024-07-17 | Filing | |
| $64.27 | 22,000 | Officer, Director | 649,620 | 2024-07-16 | Filing | |
| $63.38 | 11,000 | Officer, Director | 671,620 | 2024-07-15 | Filing | |
| $64.91 | 250 | Officer | 58,981 | 2024-07-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,524,893 | $139,222,601 | 0% | |
| 2. | 1,288,972 | $71,073,916 | 0% | |
| 3. | 592,423 | $32,666,204 | 0% | |
| 4. | 591,731 | $32,627,756 | 0% | |
| 5. | 582,428 | $32,115,080 | 2.58% |
News See All
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2023 Earnings Call Transcript
ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1, expectations were $0.8. ANI Pharmaceuticals, Inc.
13 Stocks That Will Double in 2024
Last year turned out to be wondrous for the US stock market as the S&P 500 gained over 25% compared to its 18% decline in the previous year.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the ANI Pharmaceuticals, Inc. Third Quarter 2023 Earnings Results Call. At this time, all participants are in a listen-only mode.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2023 Earnings Call Transcript
Operator: Good morning, everyone. My name is Chelsea and I will be your conference operator.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2023 Earnings Call Transcript
Operator: Good day, everyone. And welcome to today’s ANI Pharmaceuticals Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode.
11 Stocks Making Headlines After Earnings Reports
In this article, we will take a look at the 11 stocks making headlines after earnings reports.
ANI Pharmaceuticals Inc (ANIP) Fell Out Of Favor With Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is ANI Pharmaceuticals (ANIP) A Good Stock To Buy Now?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.